SHOUYAO HOLDINGS (BEIJING) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.52 CNY | -0.83% |
|
+12.61% | -6.65% |
| Sales 2022 | 1.83M 252K | Sales 2023 | 5.23M 722K | Capitalization | 8.21B 1.13B |
|---|---|---|---|---|---|
| Net income 2022 | -174M -24.03M | Net income 2023 | -186M -25.69M | EV / Sales 2022 | 1,330 x |
| Net cash position 2022 | 1.18B 163M | Net cash position 2023 | 627M 86.67M | EV / Sales 2023 | 1,450 x |
| P/E ratio 2022 |
-19.4
x | P/E ratio 2023 |
-44.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 21.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.83% | ||
| 1 week | +12.61% | ||
| Current month | -3.18% | ||
| 1 month | -3.18% | ||
| 3 months | +22.67% | ||
| 6 months | +23.22% | ||
| Current year | -6.65% |
1 week
48.01
54.42
1 month
43.1354.42
Current year
26.8155.13
1 year
26.8166.84
3 years
17.5268.00
5 years
17.5268.00
10 years
17.5268.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Jun Li
CEO | Chief Executive Officer | 57 | 16-03-31 |
Ya Jie Wang
DFI | Director of Finance/CFO | 54 | 17-05-31 |
Ying Hui Sun
CTO | Chief Tech/Sci/R&D Officer | 44 | 10-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ting Li
BRD | Director/Board Member | 35 | 21-06-30 |
Wen Jun Li
CEO | Chief Executive Officer | 57 | 16-03-31 |
Xin He Xu
BRD | Director/Board Member | 50 | 19-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 51.52 | -0.83% | 566,291 |
| 24-04-29 | 51.95 | -0.90% | 593,885 |
| 24-04-26 | 52.42 | +0.59% | 703,819 |
| 24-04-25 | 52.11 | +3.19% | 992,217 |
| 24-04-24 | 50.5 | +3.40% | 805,477 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Shouyao Holdings Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main business is the research and development of small molecule innovative drugs in the clinical stage. The Company's main products include anaplastic lymphoma kinase (ALK) kinase inhibitors, selective inhibitors and others. The Company's pharmaceutical products are used in key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as disease areas such as type II diabetes. The Company mainly operates in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.65% | 1.06B | |
| +29.68% | 699B | |
| +25.07% | 571B | |
| -4.35% | 364B | |
| +17.65% | 326B | |
| +3.77% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -3.79% | 154B |
- Stock Market
- Equities
- 688197 Stock
